Unresectable melanoma with superficial or superficial and visceral metastases MedDRA version: 21.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864
Conditions
Interventions
Product Name: PEMBROLIZUMAB (KEYTRUDA)
Product Code: [MK-3475]
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: PEMBROLIZUMAB
Current Sponsor code: MK-3475
Concentration unit
Sponsors
ISTITUTO EUROPEO DI ONCOLOGIA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Have a histologically confirmed advanced melanoma stages III b/c or IV, with at least the following superficial lesions: 5 lesions if diameter 1 cm. 2. Could have received previous therapy included CT, antiCTLA4 or antiBRAF/antiMEK treatment or be treatment naïve. 3. Be willing and able to provide written informed consent/assent for the trial. 4. Be ¿ 18 years of age on day of signing informed consent. 5. Have measurable disease based on RECIST 1.1. 6. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor. 7. Have a performance status = 2 on the ECOG Performance Scale. (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.) 8. Demonstrate adequate organ function as defined in 9. Have a baseline total body CT scan (brain MRI if brain metastasis are suspected) a. Patients with brain metastasis are allowed to participate if previously treated and brain lesion stability or inactivity is demonstrated. Patients with a history of brain metastasis are required to have a pre-baseline brain MRI at least 60 days (2 months) before the Screening/Baseline visit (Visit 1) for comparison to the Screening (Visit 1) MRI. Patients for whom MRI is contraindicated will undergo head CT. Stable/inactive disease is determined by comparing the pre baseline and screening/baseline MRI/CT results. b. Patients presenting with brain metastasis at Screening/Baseline who had no known previous brain involvement and who had no brain MRI/CT tests at least 60 days (2 months) before Screening/Baseline are considered screening failures and will be excluded from study enrollment. 10. Have cutaneous or subcutaneous metastases from melanoma that are accessible for the application of electric pulses using the single use, sterile CLINIPORATOR™ electrodes (5 lesions if diameter 1 cm). For patients presenting with more than 7 lesions, the lesions with the largest diameters that fall within the 3 months. 14. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 15. Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is
Exclusion criteria
Exclusion criteria: 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or has any ongoing treatment for melanoma or with any non-study anticancer therapy or immunosuppressive agent. 2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 3. Has a known history of active TB (Bacillus Tuberculosis) 4. Hypersensitivity to pembrolizumab or any of its excipients or known allergies to Bleomycin. 5. Has received a cumulative lifetime dose of Bleomycin exceeding 250 mg/m2 6. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 7. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. 8. Patient has a history of a malignancy (other than the disease under treatment in the study) within 5 years prior to first study drug administration. This should exclude adequately treated Stage 1 or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other in situ cancers. Shorter intervals can be considered after discussion with Merck. 9. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 10. Has epilepsy. 11. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 12. Has a history of (no-infectious) pneumonitis that require steroids or current pneumonitis. 13. Has an active infection requiring systemic therapy. 14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: to evaluate safety and efficacy (in terms of improvement of the local and systemic response rates) of the combined treatment with pembrolizumab e elettrochemotherapy ;Secondary Objective: 1)Disease control rate (complete response + partial response + SD) 2)Progression Free Survival 3)Correlation between clinical and radiological immune responses. 4)Durable local disease progression-free survival at 36 weeks (day 252 = Visit 13), 48 weeks (Visit 16), 60 (Visit 19) and every 12 weeks up two years 5)Survival at 2 years (Follow-up will be continued every 12 weeks for 2 years). 6)Safety of the combination 7)Toxicity of the combination 8)Quality of life (EORTC questionnaire Pain Visual Scale);Primary end point(s): Overall response rate (complete response + partial response);Timepoint(s) of evaluation of this end point: Every 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Disease control rate (complete response + partial response + SD) ; Correlation between clinical and radiological immune responses; Progression Free Survival; Durable local disease progression-free survival ; Overall Survival ; safety; Toxicity; Quality of life;Timepoint(s) of evaluation of this end point: end of treatment; 2 years; End of treatment; at 36 weeks (day 252 = Visit 13), 48 weeks (Visit 16), 60 (Visit 19) and every 12 weeks up two years ; Survival at 2 years (Follow-up will be continued every 12 weeks for 2 years) ; end of treatment; end of treatment; end of treatment | — |
Countries
Italy
Contacts
Public ContactUfficio Studi Clinici ed Attività R
Istituto Europeo di Oncologia
Outcome results
None listed